Ghrelin agonist (TZP-101): Safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: A phase I, first-in-human study

Journal of Clinical Pharmacology

Volumn 48, Issue 2, 2008, Pages 193-202

  Lasseter, Kenneth C ^a   Shaughnessy, Laura ^b   Cummings, David ^c   Pezzullo, John C ^d   Wargin, William ^d   Gagnon, Rene ^b   Oliva, Jesus ^a   Kosutic, Gordana ^b,d  

^a PharmaNet Development Group Inc   (United States)

^b Tranzyme Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d PK PM Associates LLC ^*  (United States)

Author keywords

Ghrelin; Motility; Phase I; Receptors; Tolerability

Indexed keywords

GROWTH HORMONE SECRETAGOGUE RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; PLACEBO; TPZ 101; TZP 101; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART RATE; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; LOWER ABDOMINAL PAIN; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; ORTHOSTATIC HYPERTENSION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMACH MOTILITY;

ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; BRADYCARDIA; DIARRHEA; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GHRELIN; GROWTH HORMONE; HALF-LIFE; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 38349084347     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007310380     Document Type: Article

References (29)

1. Cummings DE Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006 ; 89 (1). 71-84.
2. Levin F., Edholm T., Schmidt PT, et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab. 2006 ; 91: 3296-3302.
3. Dass NB, Munonyara M., Bassil AK, et al. Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience. 2003 ; 120: 443-453.
4. Fujino K., Inui A., Asakawa A., Kihara N., Fujimura M., Fujimiya M. Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats. J Physiol. 2003 ; 550 (pt 1). 227-240.
5. Edholm T., Levin F., Hellström PM, Schmidt PT Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regul Pept. 2004 ; 121: 25-30.
6. Kitazawa T., De Smet B, Verbeke K, Depoortere I, Peeters TL. Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro. Gut. 2005 ; 54: 1078-1084.
7. Tomasetto C., Wendling C., Rio MC, Poitras P. Identification of cDNA encoding motilin related peptide/ghrelin precursor from dog fundus. Peptides. 2001 ; 22: 2055-2059.
8. Trudel L., Tomasetto C., Rio MC, et al. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol. 2002 ; 282: G948 - G952.
9. Trudel L., Bouin, Tomasetto C, et al. Two new peptides to improve post-operative gastric ileus in dog. Peptides. 2003 ; 24: 531-534.
10. Poitras P., Polvino WJ, Rocheleau B. Gastrokinetic effect of ghrelin analog RC-1139 in the rat: effect on post-operative and on morphine induced ileus. Peptides. 2005 ; 26: 1598-1601.
11. Murray CD, Martin NM, Patterson M., et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double-blind, placebo-controlled, cross-over study. Gut. 2005 ; 54: 1693-1698.
12. Binn M., Albert C., Gougeon A., et al. Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. Peptides. 2006 ; 27: 1603-1606.
13. Tack J., Depoortere I., Bisschops R., et al. Influence of ghrelin on interdigestive gastrointestinal motility in man. Gut. 2006 ; 55: 327-333.
14. Ankersen M., Kramer-Nielsen K., Kruse Hansen T., Raun K., Sehested Hansen B. Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal. Eur J Med Chem. 2000 ; 35: 487-497.
15. Fraser GL, Hoveyda HR, Venkova K., et al. Pharmacological separation of the gastrointestinal and endocrine effects of ghrelin using a novel GHS-R1a agonist. Neurogastroenterol Motil. 2005 ; 17 (suppl 2 ).
16. Venkova K., Fraser G., Hoveyda H., et al. Ghrelin agonist activity in a rat model of postoperative ileus and opioid-delayed gastrointestinal motility. Poster presentation: Digestive Disease Week, May 20-25, 2006 ; Los Angeles, CA.
17. Nagaya N., Kojima M., Uematsu M., et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regulatory Integrative Comp Physiol. 2001 ; 280: R1483 - R1487.
18. Nagaya N., Miyatake K., Uematsu M., et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab. 2001 ; 86: 5854-5859.
19. Tack J., Depoortere I., Bisschops R., Verbeke K., Janssens J., Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther. 2005 ; 22: 847-853.
20. Food and Drug Administration/Center for Drug Evaluation and Research (FDA/CDER). Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville, MD: FDA/CDER ; 2005.
21. Heinrichs C., Colli M., Yanovski JA, et al. Effects of fasting on the growth plate: systemic and local mechanisms. Endocrinology. 1997 ; 138: 5359-5365.
22. De Marinis L., Mancini A., Valle D., et al. Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects. Horm Metab Res. 2000 ; 32: 152-156.
23. Chen JW, Hojlund K., Beck-Nielsen H., Sandahl Christiansen J., Orskov H., Frystyk J. Free rather than total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. J Clin Endocrinol Metab. 2005 ; 90: 366-371.
24. Ghigo E., Arvat E., Broglio F., et al. Endocrine and nonendocrine activities of growth hormone secretagogues in humans. Horm Res. 1999 ; 51: 9-15.
25. Guan XM, Yu H., Palyha OC, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res. 1997 ; 48: 23-29.
26. Date Y., Murakami N., Toshinai K., et al. The role of the gastric afferent vagal nerve in ghrelin nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 2002 ; 123: 1120-1128.
27. van den Hoek AM, Voshol PJ, Karnekamp BN, et al. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes. 2004 ; 53: 2529-2534.
28. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000 ; 141: 4325-4328.
29. Heijboer AC, van den Hoek AM, Parlevliet ET, et al. Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice. Diabetologia. 2006 ; 49: 732-738.